XELOX方案同步放化疗治疗晚期直肠癌的疗效观察

Efficacy Observation of Concurrent Radiotherapy and Chemotherapy with XELOx Regimen in the Treat ofAdvancedRectalCancer

目的:探究晚期直肠癌患者执行XELOX方案同步放化疗的效果。方法:选取2016年1月至2019年6月,本院治疗的108例晚期直肠癌患者,采用双盲法分为观察组和对照组,各54例。其中对照组患者执行XELOX方案的单一化疗,观察组患者执行XELOX方案化疗的同时开展同步放疗。比较2组干预成效(治疗有效率、远期生存率、远期复发与病灶转移率、不良反应发生率与生活质量评分)。结果:观察组总有效率为87.04%,高于对照组的70.37%(P<0.05)。观察组2年、3年远期生存率为77.78%和64.81%,高于对照组的51.85%和29.63%(P<0.05),且生活质量各维度评分均高于对照组(P<0.05)。观察组远期复发率为18.52%、远期转移率为3.7%,均低于对照组的37.04%和18.52%(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:XELOX方案同步放化疗治疗晚期直肠癌的有效性和安全性均较高,值得临床推广应用。

Objective To investigate the effect of concurrent chemoradiotherapy with XELOX regimen in patients with advanced rectal cancer.Methods A total of 108 patients with advanced rectal cancer treated in our hospital from January 2016 to June 2019 were selected and divided into the observation group and the control group by double-blind method,with 54 cases in each group.Patients in the control group simply received chemotherapy with XELOX regimen,while patients in the observation group received concurrent radiotherapy and chemotherapy with XELOX regimen.The intervention effects(total effective rate,long-term survival rate,long-term recurrence and metastasis rate,incidence of adverse reactions and quality of life score)were compared between the two groups.ResultsThe total effective rate was 87.04%in the observation group,which was higher than 70.37%in the control group(P<0.05).The two-year and three-year long-term survival rates of the observation group were 77.78%and 64.81%,which were higher than 51.85%and 29.63%of the control group(P<0.05).The scores of all dimensions of quality of life in the observation group were higher than those in the control group(P<0.05).The long-term recurrence rate and long-term metastasis rate of the observation group were 18.52%and 3.7%,which were lower than 37.04%and 18.52%of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy and safety of concurrent radiotherapy and chemotherapy with XELOX regimen in the treatment of advanced rectal cancer are high,which is worthy of clinical application.